2016
Moderate Alcohol Consumption and Chronic Disease: The Case for a Long‐Term Trial
Mukamal KJ, Clowry CM, Murray MM, Hendriks HF, Rimm EB, Sink KM, Adebamowo CA, Dragsted LO, Lapinski PS, Lazo M, Krystal JH. Moderate Alcohol Consumption and Chronic Disease: The Case for a Long‐Term Trial. Alcohol Clinical And Experimental Research 2016, 40: 2283-2291. PMID: 27688006, PMCID: PMC5073014, DOI: 10.1111/acer.13231.Peer-Reviewed Original ResearchConceptsModerate alcohol consumptionChronic diseasesAlcohol consumptionRandomized trialsLong-term clinical trialsCoronary heart diseaseMajor chronic diseasesStrong epidemiological associationLong-term trialsGold standard evidenceNutritional interventionHeart diseaseClinical trialsBreast cancerEpidemiological associationModerate drinkingYears durationClinical investigatorsBiological mediatorsAvailable evidenceDiseaseObserved associationsTrialsStandard evidenceVariety of settings
2002
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 2002, 7: s71-s80. PMID: 11986998, DOI: 10.1038/sj.mp.4001021.Peer-Reviewed Original ResearchConceptsCortical GABA levelsMood-stabilizing treatmentMood disordersGABA levelsΓ-amino-butyric acid (GABA) systemMood-stabilizing agentsGlutamate receptor functionDevelopment of medicationsGABA deficitAvailable antidepressantsGABAergic modulationAntimanic effectsGlutamatergic activityClinical evidenceNovel antidepressantsGABA systemAntidepressant drugsNew agentsReceptor functionAvailable evidenceReceptor targetsAntidepressantsDisordersGlutamateTreatment